Global Contraceptive Devices Market - Segmented by Type, Gender, and Geography - Growth, Trends, and Forecast (2022 - 2030)

SKU ID :INH-12886640 | Published Date: 01-May-2018 | No. of pages: 114
1. Introduction 1.1 Market Definition 2. Research Methodology 3. Executive Summary 4. Key Inferences 5. Market Overview 5.1 Current Market Scenario 5.2 Porter's Five Forces Analysis 5.2.1 Bargaining Power of Suppliers 5.2.2 Bargaining Power of Consumers 5.2.3 Threat of New Entrants 5.2.4 Threat of Substitute Products and Services 5.2.5 Competitive Rivalry within the Industry 6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC) 6.1 Drivers 6.1.1 Product Innovation 6.1.2 Increasing Incidence of STDs 6.1.3 Rise in Government Initiatives to Prevent Unwanted Abortions and Pregnancies 6.2 Restraints 6.2.1 Cultural or Religious Opposition 6.2.2 Limited Access to Contraception 6.2.3 Infertility Issues 6.3 Opportunities 6.4 Key Challenges 7. Market Segmentation 7.1 By Type 7.1.1 Condoms 7.1.2 Diaphragms 7.1.3 Cervical Caps 7.1.4 Sponges 7.1.5 Vaginal Rings 7.1.6 Intra Uterine Devices 7.1.7 Implants 7.2 By Gender 7.2.1 Male 7.2.2 Female 7.3 By Geography 7.3.1 North America 7.3.1.1 United States 7.3.1.2 Canada 7.3.1.3 Mexico 7.3.1.4 Rest of North America 7.3.2 Europe 7.3.2.1 United Kingdom 7.3.2.2 Germany 7.3.2.3 France 7.3.2.4 Italy 7.3.2.5 Spain 7.3.2.6 Rest of Europe 7.3.3 Asia-Pacific 7.3.3.1 China 7.3.3.2 Japan 7.3.3.3 India 7.3.3.4 Australia 7.3.3.5 South Korea 7.3.3.6 Rest of Asia-Pacific 7.3.4 Middle East & Africa 7.3.4.1 Gcc 7.3.4.2 South Africa 7.3.4.3 Rest of the Middle East & Africa 7.3.5 South America 7.3.5.1 Brazil 7.3.5.2 Argentina 7.3.5.3 Rest of South America 8. Competitive Landscape 8.1 Mergers & Acquisition Analysis 8.2 Agreements, Collaborations, and Partnerships 8.3 New Product Launches 9. Key Players 9.1 Actavis PLC 9.2 Agile Therapeutics 9.3 Bayer Healthcare 9.4 Fuji Latex Co. Ltd 9.5 Johnson & Johnson 9.6 Lupin Pharmaceuticals 9.7 Merck & Co. 9.8 Pfizer 9.9 Reckitt Benckiser Group PLC 9.10 Teva Pharmaceuticals 9.11 The Female Health Company 9.12 Others 10. Future of the Market
Actavis Plc., Agile Therapeutics, Bayer Healthcare, Fuji Latex Co. Ltd, Johnson & Johnson, Lupin Pharmaceuticals, Merck & Co., Pfizer, Reckitt Benckiser Group Plc., Teva Pharmaceuticals, The Female Health Company
  • PRICE
  • $4250
    $8750

Our Clients